Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Oct 23;36(1):83.
doi: 10.1186/s40880-017-0251-2.

Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study

Min-Ke He  1 , Yong Le  1 , Qi-Jiong Li  1 , Zi-Shan Yu  1 , Shao-Hua Li  1 , Wei Wei  1 , Rong-Ping Guo  1 , Ming Shi  2
Affiliations
Clinical Trial

Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study

Min-Ke He et al. Chin J Cancer. .

Abstract

Background: Transarterial chemoembolization (TACE) is recommended as the standard care for unresectable hepatocellular carcinoma (HCC) at Barcelona Clinic Liver Cancer (BCLC) stage A-B. However, the efficacy of TACE on large (≥ 10 cm) stage A-B HCC is far from satisfactory, and it is proposed that hepatic artery infusion chemotherapy (HAIC) might be a better first-line treatment of this disease. Hence, we compared the safety and efficacy of HAIC with the modified FOLFOX (mFOLFOX) regimen and those of TACE in patients with massive unresectable HCC.

Methods: A prospective, non-randomized, phase II study was conducted on patients with massive unresectable HCC. The protocol involved HAIC with the mFOLFOX regimen (oxaliplatin, 85 mg/m2 intra-arterial infusion; leucovorin, 400 mg/m2 intra-arterial infusion; and fluorouracil, 400 mg/m2 bolus infusion and 2400 mg/m2 continuous infusion) every 3 weeks and TACE with 50 mg of epirubicin, 50 mg of lobaplatin, 6 mg of mitomycin, and lipiodol and polyvinyl alcohol particles. The tumor responses, time-to-progression (TTP), and safety were assessed.

Results: A total of 79 patients were recruited for this study: 38 in the HAIC group and 41 in the TACE group. The HAIC group exhibited higher partial response and disease control rates than did the TACE group (52.6% vs. 9.8%, P < 0.001; 83.8% vs. 52.5%, P = 0.004). The median TTPs for the HAIC and TACE groups were 5.87 and 3.6 months (hazard radio [HR] = 2.35, 95% confidence interval [CI] = 1.16-4.76, P = 0.015). More patients in the HAIC group than in the TACE group underwent resection (10 vs. 3, P = 0.033). The proportions of grade 3-4 adverse events (AE) and serious adverse events (SAE) were lower in the HAIC group than in the TACE group (grade 3-4 AEs: 13 vs. 27, P = 0.007; SAEs: 6 vs. 15, P = 0.044). More patients in the TACE group than in the HAIC group had the study treatment terminated early due to intolerable treatment-related adverse events or the withdrawal of consent (10 vs. 2, P = 0.026).

Conclusions: HAIC with mFOLFOX yielded significantly better treatment responses and less serious toxicity than did TACE. HAIC might represent a feasible and promising first-line treatment for patients with massive unresectable HCC.

Keywords: Hepatic artery infusion chemotherapy; Hepatocellular carcinoma; Transarterial chemoembolization; mFOLFOX.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram of patients with unresectable hepatocellular carcinoma who underwent either HAIC or TACE. HAIC hepatic artery infusion chemotherapy; TACE transarterial chemoembolization; AEs adverse events
Fig. 2
Fig. 2
Kaplan-Meier estimated progression-free survival curves of patients with unresectable hepatocellular carcinoma. Of the 79 patients, 38 underwent HAIC, and 41 underwent TACE. HAIC hepatic artery infusion chemotherapy; TACE transarterial chemoembolization
See this image and copyright information in PMC

References

    1. Chen W, Zheng R, Zeng H, Zhang S. The incidence and mortality of major cancers in China, 2012. Chin J Cancer. 2016;35(1):73. doi: 10.1186/s40880-016-0137-8. - DOI - PMC - PubMed
    1. Bruix J, Sherman M, American Association for the Study of Liver D Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. doi: 10.1002/hep.24199. - DOI - PMC - PubMed
    1. European Association For The Study Of The L, European Organisation For R, Treatment Of C EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943. doi: 10.1016/j.jhep.2011.12.001. - DOI - PubMed
    1. Verslype C, Rosmorduc O, Rougier P, Group EGW Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii41–48. doi: 10.1093/annonc/mds225. - DOI - PubMed
    1. Ryder SD, Rizzi PM, Metivier E, Karani J, Williams R. Chemoembolisation with lipiodol and doxorubicin: applicability in British patients with hepatocellular carcinoma. Gut. 1996;38(1):125–128. doi: 10.1136/gut.38.1.125. - DOI - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts